Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 February 2021 Photo UFS photo archive
The National Control Laboratory for Biological Products (NCL) Building.

There can be no compromise when it comes to the quality of medicines made available to the public.

The UFS-based National Control Laboratory for Biological Products (NCL) is a full member of the international WHO-National Control Laboratory Network for Biologicals and one of 12 laboratories worldwide contracted to perform vaccine testing for the World Health Organisation (WHO). The NCL is also the only vaccine-testing laboratory in the country that performs the final quality-control testing of all human vaccine batches marketed in South Africa on behalf of the South African Health Products Regulatory Authority (SAHPRA).

In its role as a vaccine-testing laboratory for the WHO, the NCL helps to ensure that the vaccines purchased through the WHO prequalification programme for international distribution to resource-limited countries, meet the high standards of quality, safety, and efficiency. 

International testing standards

The laboratory received the status of a pharmaceutical testing laboratory after the South African Accreditation System (SANAS) endorsed its quality-management systems as of a high standard according to the International Standards Organisation’s requirements.

With its international testing standards, the NCL must ensure that all its operations – from the way documents are compiled and stored, to the maintenance of equipment and infrastructure, as well as staff competency – are performed according to international guidelines.

The laboratory has all the quality systems in place to ensure high-quality test results. The certificate of Good Manufacturing Compliance received in 2019 indicates that laboratory testing is on the expected level for any pharmaceutical testing laboratory and manufacturer. This certification is very strict and means that the NCL complies with exceptionally strict standards for pharmaceutical labs anywhere in the world. The certification offers the South African Health Products Regulatory Authority, the WHO, and other national control laboratories around the world the confidence that the test results from the NCL can be trusted.

Licensed as pharmaceutical manufacturer

The laboratory is also licensed as a pharmaceutical manufacturer. Although the lab does not manufacture, it needs to comply with manufacturing standards. It is rare for a pharmaceutical testing laboratory (such as the NCL) outside of a manufacturing context to qualify for both certifications.

News Archive

Traditional medicine can play important role in modern drugs discovery
2014-11-11

Indigenous knowledge possesses a great potential to improve science. Making use of this source may lead to advanced technological innovations. This is according to Dr Sechaba Bareetseng, UFS alumnus and Indigenous Knowledge Systems (IKS) Manager at the Council for Scientific and Industrial Research (CSIR).
Dr Bareetseng recently addressed the seventh annual IKS symposium on the Qwaqwa Campus.
“Interfacing indigenous and local knowledge with scientific knowledge has the potential of encouraging and developing inventions, especially in the pharmaceutical industry,” said Dr Bareetseng.
 
“Such interfacing can also enable access to both sets of knowledge without any discrimination whatsoever. It would also encourage co-existence that would improve understanding between the two.”
 
“Traditional medicine,” said Dr Bareetseng, “can play an extended role in modern drugs discovery as it is already happening in Botswana and New Zealand. These two countries are leading this wave of new thinking in as far as drug development is concerned.”
 
Dr Bareetseng also called on established researchers to start embracing the local communities into their research.
 
“Contemporary scientific research demands that local communities must co-author research conducted within and with them by the universities and research institutions. This would help in maintaining trust between the researchers and the communities that feel exploited. Regular feedback would also make communities feel part of the developments,” Dr Bareetseng argued.
 
He further called on the pharmaceutical companies specifically and researchers in general to convert valuable indigenous knowledge and resources into products and services of commercial value. “Plants, the ecosystem and indigenous knowledge must be preserved to provide a source of income for the local communities. Communities must also be protected from foreign exploitation of their intellectual property.”
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept